Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Utidelone Monotherapy in Refractory Advanced Soft-Tissue Sarcoma (Phase II)
ChiCTR2200062161Phase 2Not yet recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- Aug 2022
- Modality
- Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of utidelone in soft tissue sarcoma (STS), sponsored by West China Hospital of Sichuan University. Primary endpoint: Median progression-free survival. Planned start Aug 2022; status: not yet recruiting.
02
Drugs
utidelone
03
Conditions
soft tissue sarcoma (STS)
Beyond the preview
Go deeper on ChiCTR2200062161.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200062161.